Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy

被引：1
|
作者：
Barker, Kenneth [1 ]
Koza, Shannon [2 ]
Katsanis, Emmanuel [2 ,3 ,4 ,5 ,6 ]
Husnain, Muhammad [1 ,2 ]
机构：
[1] Univ Arizona, Dept Med, Tucson, AZ 85721 USA
[2] Univ Arizona, Canc Ctr, Tucson, AZ USA
[3] Univ Arizona, Dept Immunobiol, Tucson, AZ USA
[4] Univ Arizona, Dept Med, Tucson, AZ USA
[5] Univ Arizona, Dept Pathol, Tucson, AZ USA
[6] Univ Arizona, Dept Pediat, Tucson, AZ USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 11期
关键词：
CYTOKINE RELEASE SYNDROME; ANGIOPOIETIN-1;
D O I：
10.1038/s41409-023-02083-4
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1267 / 1269
页数：3
相关论文
共 50 条
  • [41] Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
    Drillet, Gaelle
    Lhomme, Faustine
    De Guibert, Sophie
    Manson, Guillaume
    Houot, Roch
    [J]. BLOOD ADVANCES, 2023, 7 (04) : 537 - 540
  • [42] CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
    Gauthier, Jordan
    Cearley, Aisling
    Perkins, Paula
    Kirk, Angela
    Shadman, Mazyar
    Williamson, Staci
    Myers, Jessie
    Chen, Andy I.
    Nagle, Sarah
    Hayes-Lattin, Brandon M.
    Schachter, Levanto Gershon
    Maloney, David G.
    Turtle, Cameron John
    Sorror, Mohamed Lotfy
    Maziarz, Richard T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] The correlation between cardiac biomarkers and serum cytokines after CAR-T therapy
    Sunayama, I.
    Min, K. D.
    Orihara, Y.
    Oboshi, M.
    Yoshihara, S.
    Yoshihara, K.
    Tamaki, H.
    Teramoto, M.
    Nishimura, K.
    Eguchi, A.
    Naito, Y.
    Higasa, S.
    Asakura, M.
    Ishihara, M.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [44] GLUCOSE-MEDIATED AND TOLBUTAMIDE-MEDIATED INSULIN-RESPONSE AFTER PRE-INFUSION WITH ETHANOL
    KUHL, C
    ANDERSEN, O
    [J]. DIABETES, 1974, 23 (10) : 821 - 826
  • [45] The expansion of targetable biomarkers for CAR T cell therapy
    Townsend, Michelle H.
    Shrestha, Gajendra
    Robison, Richard A.
    O'Neill, Kim L.
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [46] The expansion of targetable biomarkers for CAR T cell therapy
    Michelle H. Townsend
    Gajendra Shrestha
    Richard A. Robison
    Kim L. O’Neill
    [J]. Journal of Experimental & Clinical Cancer Research, 37
  • [47] A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
    Liu, Yang
    Jie, Xingxing
    Nian, Li
    Wang, Ying
    Wang, Congyue
    Ma, Jin
    Jiang, Jingjing
    Wu, Qingyun
    Qiao, Jianlin
    Chen, Wei
    Cao, Jiang
    Yan, Zhiling
    Shi, Ming
    Cheng, Hai
    Zhu, Feng
    Sang, Wei
    Li, Depeng
    Chen, Chong
    Xu, Kailin
    Li, Zhenyu
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
    Qi, Xingxing
    Li, Juan
    Luo, Pan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [49] CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY IN CAR-T CELL THERAPY PATIENTS
    Delrosario, Maria Regina
    Davison, Lisa
    Schwen, Sarah
    [J]. ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [50] APOPTOTIC CELLS THERAPY FOR THE PREVENTION OF CYTOKINE RELEASE SYNDROME (CRS) IN CAR T-CELL THERAPY
    Mevorach, D.
    [J]. CYTOTHERAPY, 2017, 19 (05) : S10 - S10
12345